KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $10.9 million.

  • Aquestive Therapeutics' Accounts Payables rose 4348.92% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 4348.92%. This contributed to the annual value of $10.3 million for FY2024, which is 1524.76% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Accounts Payables stood at $10.9 million for Q3 2025, which was up 4348.92% from $12.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' Accounts Payables' 5-year high stood at $12.4 million during Q1 2023, with a 5-year trough of $5.7 million in Q2 2024.
  • Its 5-year average for Accounts Payables is $9.4 million, with a median of $9.9 million in 2022.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 5921.11% in 2021, then surged by 10981.39% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Accounts Payables (Quarter) stood at $8.3 million in 2021, then increased by 19.63% to $9.9 million in 2022, then decreased by 10.26% to $8.9 million in 2023, then rose by 15.25% to $10.3 million in 2024, then grew by 5.62% to $10.9 million in 2025.
  • Its Accounts Payables was $10.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.3 million in Q1 2025.